Novartis (NOVN) Given a CHF 98 Price Target at Goldman Sachs Group

Novartis (VTX:NOVN) has been given a CHF 98 target price by Goldman Sachs Group in a note issued to investors on Wednesday, Borsen Zeitung reports. The firm presently has a “buy” rating on the stock.

Several other equities analysts also recently commented on the stock. UBS Group set a CHF 82 price target on shares of Novartis and gave the company a “neutral” rating in a research note on Wednesday. Deutsche Bank set a CHF 85 price target on shares of Novartis and gave the company a “neutral” rating in a research note on Friday, April 5th. Barclays set a CHF 75 price target on shares of Novartis and gave the company a “sell” rating in a research note on Friday, February 1st. JPMorgan Chase & Co. set a CHF 85 price target on shares of Novartis and gave the company a “sell” rating in a research note on Friday, February 1st. Finally, Jefferies Financial Group set a CHF 105 price objective on shares of Novartis and gave the stock a “buy” rating in a research report on Wednesday, January 30th. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the company’s stock. Novartis has an average rating of “Hold” and an average target price of CHF 88.71.

Novartis has a one year low of CHF 72.45 and a one year high of CHF 88.30.

Novartis Company Profile

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Featured Article: Treasury Bonds

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.